Aim: To assist therapeutic dose adjustment in clinic, a reliable concentration measurement is quite necessary for therapeutic drug monitoring. Results: A UHPLC–MS/MS bioassay for simultaneous determination of methotrexate, imatinib and dasatinib using isotope dilution internal standardization has been established and fully validated as per China Food and Drug Administration guideline. After a simple protein precipitation, the analytes were separated by a gradient elution within 3 min and mass detection was performed via ESI⁺ mode with SRM. The calibration curves were in the range of 5–100 ng/ml for methotrexate, 25–5000 ng/ml for imatinib and 1–250 ng/ml for dasatinib. Imprecision and inaccuracy values were ≤9.44% and ≤12.81% for all analytes, respectively. Conclusion: The developed method is appropriate for therapeutic drug monitoring, being applied to help individualized therapy in patients with acute lymphoblastic leukemia.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 381(9881), 1943–1955 (2013).
MedlineGoogle Scholar
2. Pui CH, Yang JJ, Hunger SP et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J. Clin. Oncol. 33(27), 2938–2948 (2015).
Medline CASGoogle Scholar
3. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N. Engl. J. Med. 373(16), 1541–1552 (2015).
Medline CASGoogle Scholar
4. Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment of acute lymphoblastic leukemia. Leuk. Lymphoma 60(11), 2606–2621 (2019).
Medline CASGoogle Scholar
5. De Moerloose B, Suciu S, Bertrand Y et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized Phase 3 trial 58951. Blood 116(1), 36–44 (2010).
MedlineGoogle Scholar
6. Roberts KG, Li Y, Payne-Turner D et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371(11), 1005–1015 (2014).
MedlineGoogle Scholar
7. Ramsey LB, Mizuno T, Vinks AA, O'Brien MM. Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. Pediatr. Blood Cancer 66(5), e27618 (2019).
MedlineGoogle Scholar
8. Pommert L, Liberio N, Ng JS et al. Concurrent imatinib dosing with high-dose methotrexate leads to acute kidney injury and delayed methotrexate clearance in pediatric patients with philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 43(2), e296–e300 (2021). • Gives an introduction of necessary of therapeutic drug monitoring for methotrexate and tyrosine kinase inhibitors.
Medline CASGoogle Scholar
9. Chen AR, Wang YM, Lin M, Kuo DJ. High-dose methotrexate in pediatric acute lymphoblastic leukemia: predictors of delayed clearance and the effect of increased hydration rate on methotrexate clearance. Cureus 12(6), e8674 (2020).
MedlineGoogle Scholar
10. De Moerloose B, Suciu S, Bertrand Y et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized Phase 3 trial 58951. Blood 116(1), 36–44 (2010).
MedlineGoogle Scholar
11. Lian LJ, Lin B, Cui X et al. Development and validation of UHPLC-MS/MS assay for therapeutic drug monitoring of high-dose methotrexate in children with acute lymphoblastic leukemia. Drug Des. Devel. Ther. 14, 4835–4843 (2020). • Our method was improved and expanded based on this published bioassay.
Medline CASGoogle Scholar
12. Rule G, Chapple M, Henion J. A 384-well solid-phase extraction for LC/MS/MS determination of methotrexate and its 7-hydroxy metabolite in human urine and plasma. Anal. Chem. 73(3), 439–443 (2001).
Medline CASGoogle Scholar
13. Xinxin R, Zhipeng W, Yunlei Y et al. Simultaneous quantification of methotrexate and its metabolite 7-hydroxy-methotrexate in human plasma for therapeutic drug monitoring. Int. J. Anal. Chem. 2019, 1536532 (2019).
MedlineGoogle Scholar
14. Chinese Pharmacopoeia Commission. The Pharmacopoeia of People's Republic of China. In: Biological Samples Quantitative Analysis Method Validation Guidelines, Chinese Pharmacopoeia Commission. Beijing, China, 466–472 (2015).
Google Scholar
15. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 11, 694–703 (2006).
Medline CASGoogle Scholar
16. Barbara DM, Stefan S, Yves B et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951. Blood 116(1), 36–44 (2010).
MedlineGoogle Scholar
17. Miura M. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol. Pharm. Bull. 38(5), 645–654 (2015).
Medline CASGoogle Scholar
18. Boos J, Werber G, Ahlke E et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur. J. Cancer 32A(9), 1544–1550 (1996).
Medline CASGoogle Scholar
19. Steele WH, Lawrence JR, Stuart JF, McNeill CA. The protein binding of methotrexate by the serum of normal subjects. Eur. J. Clin. Pharmacol. 15(5), 363–366 (1979).
Medline CASGoogle Scholar
20. Suttorp M, Bornhäuser M, Metzler M, Millot F, Schleyer E. Pharmacology and pharmacokinetics of imatinib in pediatric patients. Expert Rev. Clin. Pharmacol. 11(3), 219–231 (2018).
Medline CASGoogle Scholar
21. Kamath AV, Wang J, Lee FY, Marathe PH. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother. Pharmacol. 61(3), 365–376 (2008).
Medline CASGoogle Scholar

Vol. 13, No. 19

Metrics

Downloaded 105 times

History

Received 22 July 2021

Accepted 21 September 2021

Published online 4 October 2021

Published in print October 2021

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download